

BILL SUMMARY
2nd Session of the 60th Legislature

Bill No.:	HB 3834
Version:	INT
Request Number:	15886
Author:	May
Date:	2/6/2026
Impact: Please see previous summary of this measure	

Research Analysis

HB 3834, as introduced, creates the "Oklahoma Breakthrough Therapy Act," which requires an ibogaine drug developer to provide certain information before the State Department of Health may contract with them. The Department must also negotiate a contract with the drug developer that requires the developer to match the state's investment in clinical trials, to provide specified reporting, to establish a plan to ensure broad and accessible ibogaine treatment access following approval by the United States Food and Drug Administration, and to provide a plan to recognize the state's economic interest in the intellectual property generated over the clinical trials. The Department may also make additional terms and reasonable deviations in negotiating a contract provided the contract is fair and creates at least a substantially equivalent value for the state.

The drug developer must prepare and submit a quarterly report to the State Department of Health and the Department must annually submit a report to the Legislature by Dec. 1 each year until the clinical trials are finished. The measure requires the ibogaine intellectual property account to be created in the Office of the State Treasurer. Expenditures from this account will only be used for programs or research benefitting at-risk populations that suffer from conditions treatable with ibogaine. Medical professionals licensed in the state will not be subject to adverse licensing action for recommending psilocybin or ibogaine therapy services.

Prepared By: Suzie Nahach, House Research Staff

Fiscal Analysis

The measure is currently under review and impact information will be completed.

Prepared By: House Fiscal Staff

Other Considerations

None.